Tazverik® (tazemetostat) targets histone methyltransferase EZH2 (responsible for H3K27me2/3) and has been approved for the treatment of epithelioid sarcoma and follicular lymphoma and solid tumours [107–110]. The gene discussed is PRDM9; the disease is epithelioid sarcoma.